Trial site
Southern California Clinical Research
Santa Ana, California 92701, United StatesNot linked to an institution yet
- 17running trials
- 1closed trial
The trials here
What the 18 trials at this site are about, from their registry records.
- Status
- Active, not recruiting10 trials
- Recruiting6 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company8 trials
- Pfizer5 trials
- Amgen3 trials
- Alumis Inc2 trials
Running trials
Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Contact: Wayne Ho (principal investigator)
Recruiting
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500· Phase 3· Pfizer· Source
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235· Phase 3· Amgen· Source
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· Phase 3· Amgen· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Wayne Ho (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: Wayne Ho (principal investigator)
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error